New Technology– category –
-
Big Data and Predictive Analytics Revolutionize Bioreactor Performance, Enhancing Robustness, Efficiency, and Decision-Making
Facebook (Infors HT) Switzerland Overview The application of big data and predictive analytics to bioreactors is highlighted as maximizing potential by enhancing process robustness, efficiency, and decision-making. Utilizing real-time da... -
Drug Discovery News Highlights Rising Complexity in Biologics Manufacturing: Urges Manufacturability by Design, Raw Material Quality, and Process Intensification
Drug Discovery News USA Overview Drug Discovery News reports on the increasing complexity in manufacturing biologics, cell-based therapies (including CAR T), viral vectors, and oligonucleotides. The article identifies key challenges such... -
BubbleGen: Bracco Imaging’s Bead-Free Microbubble Technology Revolutionizes CAR-T Cell Selection
Manufacturing Chemist Italy Overview Bracco Imaging has launched its BubbleGen CD3+ T Cell Selection Kit, a pioneering bead-free technology set to transform CAR-T cell manufacturing. Leveraging gas-core, lipid-shell microbubbles for gent... -
Amsbio Launches StemFit Basic04CT: Animal-Origin-Free iPSC Culture Medium Enables One-Step Media Switch, Streamlining Clinical Manufacturing
Lab Manager International Overview Amsbio has released performance data for StemFit Basic04CT, an animal-origin-free, chemically defined medium for human pluripotent stem cell (hPSC) culture, enabling a one-step media switch. This GMP-qu... -
Max Delbrück Center Research Reveals ‘Quality Over Quantity’ in CAR-T Therapy, Identifying Key Factors for Low-Dose Efficacy to Enable Personalized Treatment and Cost Reduction
Max Delbrück Center for Molecular Medicine Germany Overview A research consortium from the Max Delbrück Center, publishing in "Nature Communications," identified key biological factors influencing CAR-T cell therapy effectiveness at lowe... -
UCLA Scientists Mass-Produce Ready-to-Use Cord Blood-Derived T Cells for Solid Tumors in 6 Weeks at $5,000/Dose, Avoiding GvHD Risk
UCLA USA Overview UCLA researchers have developed a platform to mass-produce cancer-fighting T cells from cord blood stem cells, engineered to target solid tumors. This innovative approach generates trillions of therapeutic cells (thousa... -
Democratizing Immunotherapy: Tec de Monterrey Pioneers Cost-Effective NK Cell Production Using Autologous Plasma
Facebook (Tec de Monterrey) Mexico Overview A research team at Tec de Monterrey's Toluca campus in Mexico has developed an innovative method to optimize natural killer (NK) cell cultures, utilizing readily available autologous human plas... -
Next-Gen CAR-T Manufacturing Reduces Production Time to 1-2 Days, Explores Decentralized Models for Potent Cells
Bioprocess International USA Overview An article in Bioprocess International highlights advancements in next-generation CAR-T cell therapy manufacturing, which are set to reduce production times to as little as one or two days, yielding ... -
AI-Integrated Bioreactors Revolutionize Allogeneic Cell Therapy Manufacturing, Unlocking Scalability and Affordability
sanandres.uep.edu.py Paraguay Overview Allogeneic cell therapy manufacturing is undergoing a significant transformation, driven by the integration of automated, closed-system bioreactors and AI/machine learning for real-time monitoring. ... -
Automated iPSC Manufacturing Achieves Monoclonal Lines in Seven Weeks, Paving Way for Cost-Efficient Clinical Autologous Therapies
bioRxiv Unknown Overview A new study introduces a highly efficient, standardizable, and automatable workflow for generating monoclonal induced pluripotent stem cell (iPSC) lines from human skin biopsies, including comprehensive quality c...
